Program (speakers and titles)

MAY 4TH

9:00 Registration

9:15 Welcome and Opening Remarks

A.MEDICINAL CHEMISTRY

Chairpersons: Philippe M. Loiseau and Thomas J. Schmidt

9:30-10:15 Plenary Lecture A: New drugs against Onchocerca filarial parasites: Lessons from the bovine model in Cameroon. Alfons Renz. University of Tübingen, Germany

10:15-10:45 Coffee break-Poster viewing

10:45- 11:45 Oral communications (OC), 15+5 min/ communication

  • OC 1A:Looking for hits and leads through library screening in the NMTRYPI platform in the field of trypanosomatidic infections. Maria Paola Costi, Università Degli Studi di Modena e Reggio Emilia
  • OC 2A: Antileishmanial activity of methylselenocarbamates. Mikel Etxebeste. Instituto de Salud Tropical University of Navarra (ISTUN), Spain
  • OC 3A:Generating evidence for a single drug combination dose (ivermectin+albendazole) to improve mass drug administration programmes to control soil transmitedhelmints, strongyloidesstercoralis included, in Bahir Dar, Amhara region, Ethiopia.Juan José de los Santos Sanz-Bustillo. Mundo Sano Foundation

11:45-12:45 Poster Flash Presentation (PF), 4+1 min/ poster

  • PF 1 On the road to functional understanding the divergent actin 2, a new target for malaria transmission blocking. Maria Andreadaki, Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
  • PF 2: Leishmania major nucleuslocated Yinp protein is a genotoxic drugs target. Miriam Algarabel. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 3: Involvement of the serine/threonine kinase – Jean3 – in leishmania infectivity. Celia Fernández Rubio, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 4: Lactococcus lactis HSP65 producer as an alternative therapy for cutaneous leishmaniasis. Juliana Rebouças, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
  • PF 5: Leishmania vaccination using microneedles and nucleosomal histones. Esther Moreno, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Farmacia y Tecnología Farmacéutica, Spain
  • PF 6: Histone fold domain dimerization of oocyst rupture proteins (ORPs) as target for antimalarial drugs development. Chiara Currà, Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
  • PF 7: Study and characterization of a newly discovered oncogenic domain in leishmania spp. José Peña, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 8: Exploring the scope of new arylamino alcohol derivatives: synthesis, antimalarial evaluation, toxicological studies, and target exploration. Miguel Quiliano, Instituto de Salud Tropical (ISTUN), Departamento de Química Orgánica y Farmacéutica, Spain
  • PF 9: Angiostrongylus cantonensis. Emergencia en América. Alberto Juan Dorta-Contreras. Laboratorio Central de Líquido Cefalorraquídeo (LABCEL). Facultad de Ciencias Médicas “Miguel Enríquez”, Universidad de Ciencias Médicas de La Habana, Cuba.

12:45-13:45 Lunch

B.NATURAL PRODUCTS AS ANTIPARASITIC AGENTS

Chairpersons: Harry P. de Koning and Alfons Renz

13:45-14:30 Plenary Lecture B:Antischistosomal and mosquitocidal secondary metabolites from medicinal African plants. JosphatMatasyoh, University of Egerton, Kenya

14:30-15:50 Oral communications

  • OC 1B: Drug targeting of natural products: the example of antileishmanial quinolines. Philippe M. Loiseau. Université Paris-Sud, France
  • OC 2B: Steroidal alkaloids with anti-trypanosomal activity from Holarrhena africana (Apocynaceae). Thomas J. Schmidt. Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Germany
  • OC 3B: Natural products are closer to drugs than non-drugs and can find use in antiparasitic treatment. Alfonso T. García-Sosa. Institute of Chemistry, University of Tartu, Estonia
  • OC 4B: Anti-trypanosomalelemanolide sesquiterpene lactones from Vernonialasiopus O. Hoffm. Mark Kimani. Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Germany

15:50-16:35Plenary Lecture B: Antileishmanial lead-finding from Plantæ columbianæ: pursuit of proof-of-concepts using modern approaches.Ericsson Coy Nueva Granada Military University. Department of Chemistry. Bogotá, Colombia.

16:35-16:45 Coffee break-Poster viewing

16:45 – 17:15 Working session

17:30 Guided Tour

20.30 Dinner at Café Iruña

MAY 5TH

C.BIOLOGICAL TARGETS FOR CHEMOTHERAPY

Chairpersons: Juan M. Irache and JosphatMatasyoh

9:00-9:45 Plenary Lecture C: Development of nanocarriers for innovative antimalarial combination strategies. Xavier Fernández-Busquets, Institute for Global Health (ISGlobal). University of Barcelona, Spain

9:45-11:05 Oral communications

  • OC 1C: Transmission blocking targets in Plasmodium berghei mosquito midgut stages. Inga Siden-Kiamos. Foundation for Research and Technology-Hellas, Institute of Molecular Biology and Biotechnology, Heraklion, Greece.
  • OC 2C: Strategies to identify the genes encoding pyrimidine-specific transporters in protozoa. Khalid Jamaan Alzahrani. Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom; Department of Clinical Laboratory, College of Applied Medical Sciences, Taif University, Saudi Arabia.
  • OC 3C: Trypanothione reductase and superoxide dismutase as current drug targets for Trypanosoma cruzi: an overview of compounds with activity against Chagas disease. Iván Beltrán-Hortelano. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Química Orgánica y Farmacéutica, Spain.
  • OC 4C: Recent neuroimmunological findings in eosinophilic meningoencephalitis due to Angiostrongylus cantonensis.Alberto Juan Dorta-Contreras. Laboratorio Central de Líquido Cefalorraquídeo (LABCEL). Facultad de Ciencias Médicas “Miguel Enríquez”, Universidad de Ciencias Médicas de La Habana, Cuba.

11:05-11:30Coffee break-Poster viewing

D.DRUG TARGETING AND DRUG RESISTANCE

Chairpersons: Francisco J. Otero Espinar andAlfonso T. García-Sosa

11:30-12:15 Plenary Lecture D: A cell targeting nanostrategy to bypass drug resistances in African trypanosomiasis. José Luis Arias Mediano. University of Granada, Spain

12:15-13:00 Oral communications

  • OC 1D: A decrease in mitochondrial membrane potential is associated with diminazene resistance in Trypanosoma congolense. Harry P. de Koning. Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom.
  • OC 2D: An ex vivo phenotypic screening for antileishmanial drugs using infrared-transgenic cells.Rosa Mª Reguera. Dpt. Biomedical Sciences; University of León, Spain

13:00-14:30 Lunch-Poster viewing

Chairpersons: Socorro Espuelas and Fabio Rocha Formiga

14:30-15:30 Oral Communications

  • OC 3D: Developing nanoparticles for 17-AAGdelivery against Leishmania infection. Fabio Rocha Formiga.GonçaloMonizInstitute, Oswaldo Cruz Foundation (FIOCRUZ/BA), Salvador, Brazil
  • OC 4D: Lipid-based EmulsomeNanoformulations for Targeted Delivery of Antiparasites. Mehmet HikmetUcisik. Department of Biomedical Engineering, School of Engineering and Natural Sciences, Istanbul Medipol University; Medipol Regenerative and Restorative Medicine Research Center (REMER), Istanbul, Turkey.
  • OC 5D: The trypanosomatid serine/threonine protein kinase “Jean3” may confer resistance to drugs such as paromomycin.Andrés Vacas-Oleas. Instituto de Salud Tropical University of Navarra (ISTUN), Spain

15:30-16:15 Plenary lecture E: The quest for new vaccines against brucellosis. Ignacio Moriyón. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departmentof Microbiology and Parasitology, Spain.

16:15–18:00 Meeting of the Working Groups 3 and 4